Literature DB >> 69002

Enrichment of antigen-specific B lymphocytes by the direct removal of B cells not bearing specificity for the antigen.

S M Walker, G C Meinke, W O Weigle.   

Abstract

Antigen-specific B cells (ASC) were purified from other B cells by prior incubation with specific antigen followed by rosetting with erythrocytes conjugated with anti-mouse Ig and sedimenting on Ficoll-Isopaque. This procedure allowed the removal of most of the B cells, while those speicifc for the antigen used in incubation were retained. Relative to the B-cell content, ASC were enriched 64- to 132-fold. The method is highly specific in that B cells primed to two different antigens, turkey gamma globulin and sheep erythrocytes, could be separated from each other. The advantages of this indirect purification procedure over purification procedures which obtain ASC directly are the simplicity of obtaining the ASC and the ability of the ASC of respond to antigen without the addition of other cells.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 69002      PMCID: PMC2180762          DOI: 10.1084/jem.146.2.445

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  28 in total

1.  A procedure for removing red cells and dead cells from lymphoid cell suspensions.

Authors:  W F Davidson; C R Parish
Journal:  J Immunol Methods       Date:  1975-06       Impact factor: 2.303

2.  A new, simple method for the preparation of lymphocytes bearing specific receptors.

Authors:  W Haas; J W Schrader; A Szenberg
Journal:  Eur J Immunol       Date:  1974-08       Impact factor: 5.532

3.  Demonstration that antigen-binding cells are precursors of antibody-producing cells after purification with a fluorescence-activated cell sorter.

Authors:  M H Julius; T Masuda; L A Herzenberg
Journal:  Proc Natl Acad Sci U S A       Date:  1972-07       Impact factor: 11.205

4.  A modification of the hemolytic plaque assay for use with protein antigens.

Authors:  E S Golub; R I Mishell; W O Weigle; R W Dutton
Journal:  J Immunol       Date:  1968-01       Impact factor: 5.422

5.  Critical role of determinant presentation in the induction of specific responses in immunocompetent lymphocytes.

Authors:  D H Katz; E R Unanue
Journal:  J Exp Med       Date:  1973-04-01       Impact factor: 14.307

6.  Antifluorescein affinity columns. Isolation and immunocompetence of lymphocytes that bind fluoresceinated antigens in vivo or in vitro.

Authors:  D W Scott
Journal:  J Exp Med       Date:  1976-07-01       Impact factor: 14.307

7.  Separation of antigen-specific lymphocytes. II. Enrichment of hapten-specific antibody-forming cell precursors.

Authors:  W Haas
Journal:  J Exp Med       Date:  1975-05-01       Impact factor: 14.307

8.  Fate of antigen-binding cells in unresponsive and immune mice.

Authors:  J Louis; J M Chiller; W O Weigle
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

9.  Isolation of antigen-binding cells from unprimed mice: demonstration of antibody-forming cell precursor activity and correlation between precursor and secreted antibody avidities.

Authors:  M H Julius; L A Herzenberg
Journal:  J Exp Med       Date:  1974-10-01       Impact factor: 14.307

10.  2,4-Dinitrophenyl receptors on mouse thymus and spleen cells.

Authors:  D A Lawrence; H L Spiegelberg; W O Weigle
Journal:  J Exp Med       Date:  1973-02-01       Impact factor: 14.307

View more
  3 in total

1.  In vitro anamnestic immune responses and modulating factors.

Authors:  A B Stavitsky; A A Gerblich
Journal:  Mol Cell Biochem       Date:  1979-12-14       Impact factor: 3.396

2.  Resistance to Nocardia brasiliensis infection in mice immunized with either Nocardia or BCG.

Authors:  C Ximénez; E I Melendro; A González-Mendoza; A M García; A Martínez; L Ortiz-Ortiz
Journal:  Mycopathologia       Date:  1980-03-17       Impact factor: 2.574

3.  In vitro tolerance induction of primed, IgD-negative murine spleen cells.

Authors:  S M Walker; W O Weigle
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.